{"doi":"10.17615/j601-tq87","title":"Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62LloFoxP3+CD4+ T cells with limited suppressor activity","abstract":"IL-2 plays a critical role in the induction and maintenance of FoxP3-expressing regulatory T cells (FoxP3+Treg). Reduced expression of IL-2 is linked to T cell-mediated autoimmune diseases such as Type 1 diabetes (T1D), in which an imbalance between FoxP3+Treg and pathogenic T effectors exists. We investigated the contribution of IL-2 to dysregulation of FoxP3+Treg by comparing wildtype NOD mice with animals congenic for a C57BL/6-derived disease resistant Il2 allele and in which T cell secretion of IL-2 is increased (NOD.B6Idd3). Whereas NOD mice exhibited a progressive decline in the frequency of CD62LHIFoxP3+Treg due to an increase in CD62LLOFoxP3+Treg, CD62LHIFoxP3+Treg were maintained in the pancreatic lymph nodes and islets of NOD.B6Idd3 mice. Notably, the frequency of proliferating CD62LHIFoxP3+Treg was elevated in the islets of NOD.B6Idd3 versus NOD mice. Increasing levels of IL-2 in vivo also resulted in larger numbers of CD62LHIFoxP3+Treg in NOD mice. These results demonstrate that IL-2 influences the suppressor activity of the FoxP3+Treg pool by regulating the balance between CD62LLO and CD62LHI FoxP3+Treg. In NOD mice reduced IL-2 expression leads to an increase in nonsuppressive CD62LLOFoxP3+Treg, which in turn correlates with a pool of CD62LHIFoxP3+Treg with limited proliferation.","journal":"UNC Libraries","year":2020,"id":139209,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9545,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":469192,"name":"Bo Wang","orcid":"0000-0001-7633-4435","position":1,"is_corresponding":false},{"id":602517,"name":"Kevin Goudy","orcid":null,"position":2,"is_corresponding":false},{"id":533176,"name":"Roland Tisch","orcid":"0000-0001-7751-7241","position":3,"is_corresponding":false},{"id":546781,"name":"Mark C. Johnson","orcid":"0000-0003-1748-1448","position":4,"is_corresponding":false},{"id":602518,"name":"Alaina L. Garland","orcid":null,"position":5,"is_corresponding":false},{"id":433530,"name":"Chengwen Li","orcid":"0000-0003-4397-4561","position":6,"is_corresponding":false},{"id":378659,"name":"R. Jude Samulski","orcid":"0000-0001-7299-9608","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T23:17:10.185988Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}